Literature DB >> 2787718

Decreased production of interleukin-1 by monocytes from patients with lipoid nephrosis.

K Matsumoto1.   

Abstract

In order to further characterize monocyte function in patients with lipoid nephrosis (LN), we studied the production of interleukin-1 (IL-1). In this study we examined the ability of peripheral blood monocytes (PBM) from LN patients to produce this monokine in vitro under the stimulus of bacterial lipopolysaccharide (LPS). The levels of IL-1 were decreased in patients with LN compared with those in normal controls and lower in LN patients with nephrotic syndrome (NS) than in those without NS. In contrast, the values in IgA nephropathy (IgAN) patients with or without NS did not differ from normal subjects. The addition of indomethacin, an inhibitor of prostaglandin synthesis, partially restored this defect. These results suggest that the impaired IL-1 production of LN PBM is probably attributable, at least in part, to increased prostaglandin production and possibly influences the immune status of LN patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787718

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

1.  Serum and urine soluble interleukin-2 receptor in idiopathic nephrotic syndrome.

Authors:  G H Bock; J R Ongkingco; L T Patterson; J Ruley; L R Schroepfer; D L Nelson
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

Review 2.  Management of nephrotic syndrome in childhood.

Authors:  T Melvin; W Bennett
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

3.  Childhood nephrotic syndrome in relapse is associated with down-regulation of monocyte CD14 expression and lipopolysaccharide-induced tumour necrosis factor-alpha production.

Authors:  S P Chen; W Cheung; C K Heng; S C Jordan; H K Yap
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

4.  Decreased release of IL-10 by monocytes from patients with lipoid nephrosis.

Authors:  K Matsumoto
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.